Tyndale R, Aoyama T, Broly F, Matsunaga T, Inaba T, Kalow W, Gelboin H V, Meyer U A, Gonzalez F J
Department of Pharmacology, University of Toronto, Medical Sciences Center, Canada.
Pharmacogenetics. 1991 Oct;1(1):26-32. doi: 10.1097/00008571-199110000-00005.
A variant CYP2D6(C) P450 protein was found in a liver characterized by deficient microsomal metabolism of bufuralol and sparteine, prototypical substrates for the debrisoquine-sparteine drug oxidation polymorphism. This protein was present at decreased levels in liver and had a slightly different relative mobility on SDS-polyacrylamide gels. The cDNA cloning and sequencing of the variant, designated CYP2D6(C), revealed that its mRNA lacked a single codon resulting in deletion of Lys281. This was the result of a three base pair deletion at the 3' end of CYP2D6 exon 5. The CYP2D6(C) P450, produced in HepG2 cells using vaccinia virus mediated cDNA expression displayed Km values toward bufuralol, debrisoquine and sparteine that were not significantly different from wild type CYP2D6. These data suggest that the poor metabolizer phenotype in livers expressing CYP2D6(C) is not due to a catalytically defective enzyme but perhaps due to decreased levels of the P450 protein in microsomal membranes. Low microsomal CYP2D6(C) contents could result from deficient membrane insertion or decreased stability of the P450 protein. A polymerase chain reaction-based procedure, developed to detect CYP2D6(C) alleles, indicates that this variant probably represents less than 1.5% of all CYP2D6 alleles.
在一个肝脏中发现了一种变异的CYP2D6(C) P450蛋白,该肝脏的特征是对布福洛尔和司巴丁(作为去甲丙咪嗪-司巴丁药物氧化多态性的典型底物)的微粒体代谢存在缺陷。这种蛋白在肝脏中的水平降低,并且在SDS-聚丙烯酰胺凝胶上具有略微不同的相对迁移率。对该变异体(命名为CYP2D6(C))进行cDNA克隆和测序发现,其mRNA缺少一个密码子,导致赖氨酸281缺失。这是CYP2D6外显子5 3'端三个碱基对缺失的结果。使用痘苗病毒介导的cDNA表达在HepG2细胞中产生的CYP2D6(C) P450对布福洛尔、去甲丙咪嗪和司巴丁的Km值与野生型CYP2D6没有显著差异。这些数据表明,表达CYP2D6(C)的肝脏中代谢不良者表型并非由于酶的催化缺陷,而是可能由于微粒体膜中P450蛋白水平降低。微粒体中低含量的CYP2D6(C)可能是由于膜插入缺陷或P450蛋白稳定性降低所致。一种基于聚合酶链反应的方法被开发用于检测CYP2D6(C)等位基因,表明该变异体可能占所有CYP2D6等位基因的不到1.5%。